Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

盘前要闻 1、企稳信号初现！黄金白银双双反攻，杠杆抛售潮或近尾声 类型：行业 情绪影响：正面 周二，现货黄金高开，截至发稿黄金重回4800美元，日内涨超3%。现货白银向上突破83美元，日内涨 超5%。贵金属前两个交易日的暴跌让人惶恐，现货黄金上周五创下逾十年来最大单日跌势。分析指 出，量化基金去杠杆化、杠杆ETF和趋势跟踪策略头寸调整所引发的强制抛售潮，其主体部分可能已基 本释放。 2、护航万亿级赛道，十部门联合发布低空经济标准体系建设指南 类型：行业 情绪影响：正面 市场监管总局会同中央空管办等十部门联合发布《低空经济标准体系建设指南(2025年版)》。到2027 年，低空经济标准体系基本建立，基本满足低空经济安全健康发展需求。到2030年，低空经济领域标准 超过300项 ，结构优化、先进合理、国际兼容的低空经济标准体系基本形成，为低空经济安全健康发展 提供有力支撑。 3、中共中央、国务院：要建成以首都为核心的世界一流都市圈 类型：宏观 情绪影响：正面 中共中央、国务院发布关于《现代化首都都市圈空间协同规划(2023-2035年)》，规划指出，首都都市圈 是优化提升和服务保障首都功能的重要地区，要围绕完善首 ...

Major Events - ST Kaiyuan expects a negative net asset value by the end of 2025, which may lead to a delisting risk warning from the Shenzhen Stock Exchange [1] - Changfei Fiber indicates that the global fiber optic cable market is stable, with new products related to data centers representing a small proportion of total demand [1] - Litong Electronics clarifies that its liquid cooling product development is still in the early discussion stage, denying rumors of significant technological breakthroughs [1] Financial Announcements - Shanghai Yizhong reports a net profit of 64.13 million yuan for 2025, a year-on-year increase of 819.42%, driven by the inclusion of its core product in the national medical insurance directory [4] - Lianyun Technology announces a net profit of 142 million yuan for 2025, up 20.36% year-on-year, benefiting from the recovery in the storage industry and the rapid development of AI [5] Share Buybacks - Midea Group has repurchased 0.35% of its shares for a total of 1.998 billion yuan, with share prices ranging from 69.50 to 80.44 yuan [6] - XGIMI Technology plans to repurchase shares worth between 50 million and 100 million yuan for employee stock ownership plans, with a maximum price of 159.51 yuan per share [6] - GoerTek has repurchased 1.14% of its shares for a total of 1.108 billion yuan, with prices between 20.35 and 34.09 yuan [6] Contracts and Projects - Chongqing Construction has won multiple project bids, including a 673 million yuan contract for the Binzhou Qiwo Ecological Circular Industry Park [8] - Jinchengxin has signed a contract for mining and installation works at the Plang Copper Mine, with an estimated total price of 202 million yuan [9] - Far East Holdings reports that its subsidiaries signed contracts worth approximately 3.075 billion yuan in January 2026 [10] - *ST Songfa's subsidiary has signed a significant contract for the construction of a Capesize bulk carrier, valued between 70 to 100 million USD [11]

通化东宝的2025年业绩增幅，预计也将超过30倍。经公司财务部门初步测算，预计2025年归属净利润约 12.42亿元，将实现扭亏为盈。 2025年，A股医药股的业绩"冷暖交织"。Wind数据显示，截至2月1日，共有283只医药股"剧透"2025年 的业绩情况。按预告净利润上限看，共有160股的归属净利润同比增长，其中赛诺医疗成为A股药企的 净利"预增王"，最高预增超32倍。在过半数企业业绩预增的同时，也有超120家企业的业绩预减，其中 更有39股面临上市后的首次亏损，不乏智飞生物、珍宝岛、新诺威等知名企业。此外，通过业绩预告可 以发现，创新药领域正悄然迎来破晓时分。其中，荣昌生物、诺诚健华等企业实现扭亏为盈。君实生 物、盟科药业等创新药企虽未盈利，但减亏趋势明显。 赛诺医疗成"预增王" Wind数据显示，截至2月1日，按预告净利润上限看，283只披露2025年业绩预告的医药股中，共有160 股实现归属净利润同比增长。 业绩预增的个股中，药明康德、翰宇药业、康希诺、泰格医药、三生国健等65股的预告净利润同比增长 上限超100%，赛诺医疗、通化东宝、回盛生物3股的业绩增幅超10倍。 其中，赛诺医疗以最高超32倍的 ...

Core Viewpoint - The performance of A-share pharmaceutical stocks in 2025 shows a mixed outlook, with 283 companies disclosing earnings forecasts, where 160 companies expect profit growth while over 120 companies anticipate profit declines, indicating a significant divergence in the industry [1][3]. Group 1: Profit Growth - Among the 283 pharmaceutical stocks, 160 companies are expected to see a year-on-year increase in net profit, with Sino Medical (688108) leading the pack with a projected increase of over 32 times [1][3]. - Sino Medical forecasts a net profit of 43 million to 50 million yuan for 2025, representing a year-on-year growth of 2,767% to 3,233% [3]. - Other notable companies with significant profit growth include WuXi AppTec, Hanyu Pharmaceutical, and Kangxino, with 65 companies projecting a net profit increase of over 100% [3][4]. Group 2: Profit Decline - Over 120 companies are expected to report a decline in net profit for 2025, with 39 companies facing their first losses since listing, including well-known firms like Zhifei Biological and Zhenbao Island [1][5]. - Zhifei Biological anticipates a net loss of approximately 10.698 billion to 13.726 billion yuan, marking a year-on-year decline of 630% to 780% [6][7]. - The decline in the vaccine sector is attributed to decreased public willingness to vaccinate and increased vaccine hesitancy, leading to significant performance pressure across the industry [7][8]. Group 3: Innovative Drug Companies - Several innovative drug companies are reporting positive trends, with some achieving profitability or significantly reducing losses. For instance, Nocren Pharmaceutical is expected to turn a profit for the first time, projecting a net profit of around 633 million yuan [10]. - Rongchang Biopharmaceutical is also expected to turn a profit, with a projected net profit of approximately 716 million yuan, driven by strong sales of core products [10]. - Companies like Junshi Biosciences and Amgen have not yet achieved profitability but are showing a clear trend of reduced losses, indicating a gradual transition towards commercialization and revenue growth in the innovative drug sector [11].

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [12][60]. Core Insights - The report highlights significant collaborations in the innovative drug sector, including 石药集团 (Shijiazhuang Yiling Pharmaceutical) partnering with AstraZeneca for long-acting peptide drug development and receiving clinical trial approval for SYS6055 injection in China [8][37]. - The report emphasizes the robust R&D capabilities of Chinese pharmaceutical companies showcased at the 2026 JPM Healthcare Conference, suggesting investment opportunities in innovative drugs, CXO, and upstream life sciences [12][60]. - The report notes the recent release of the revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China," which aims to enhance drug innovation and regulatory processes [19][20]. Industry Data - As of January 29, 2026, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) is 51.60 times, with a valuation premium of 259% relative to the CSI 300 index [10][52]. - The report provides current prices for vitamin raw materials, with Vitamin B1 at 237.5 RMB/kg and Vitamin D3 at 130 RMB/kg, remaining stable compared to January 28 [22]. - The Chinese herbal medicine market index shows a decline of 15% year-on-year, with specific herbs like 党参 (Codonopsis) and 当归 (Angelica) experiencing price drops of 41% and 29% respectively [26]. Company Announcements - 先声药业 (Xiansheng Pharmaceutical) signed an exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, with potential milestone payments reaching up to 1.016 billion euros [36]. - 恒瑞医药 (Hengrui Medicine) received acceptance for a drug listing application and clinical trial approval for multiple products, including a breakthrough therapy designation for HRS-5346 [39][40]. - 诺诚健华 (Innovent Biologics) anticipates a revenue of approximately 2.365 billion RMB for 2025, marking a 134% year-on-year increase [41].

Market Performance - The Hong Kong stock index opened lower and continued to decline, closing down 2.08% at 27,387.11 points, while the Hang Seng Tech Index fell 2.1% to 5,718.18 points [1] - Major technology stocks experienced declines, with Alibaba down 2.37%, Tencent down 2.57%, and JD Group down 1.92% [1] - Gold stocks plummeted, with Chifeng Jilong Gold Mining down over 14% and Shandong Gold Mining down over 14% [1] - Lithium mining stocks also fell, with Ganfeng Lithium down nearly 11% and Tianqi Lithium down over 10% [1] - Education and storage chip concepts rose, with New Oriental up 5.52% and China Spring up 22.76% [1] Company Insights - Guoquan (02517.HK) expects revenue of approximately 7.75 billion to 7.85 billion yuan in 2025, a year-on-year increase of about 19.8% to 21.3%, with net profit projected at 443 million to 463 million yuan, up 83.7% to 92.0% [2] - Hengrui Medicine (01276.HK) has received acceptance for a new indication application for its innovative drug, which may provide a new treatment option for patients with unresectable liver cancer [2] - Gilead Sciences-B (01672.HK) reported positive top-line results for its oral FASN inhibitor in treating acne [2] - Baiaosaitu-B (02315.HK) anticipates revenue of 1.369 billion to 1.389 billion yuan in 2025, a year-on-year increase of 39.61% to 41.65%, with net profit expected to rise by 384.26% to 443.88% [2] - Nocera (09969.HK) expects total revenue of approximately 2.365 billion yuan in 2025, a year-on-year growth of about 134%, and aims to achieve profitability with a net profit of around 633 million yuan [2] Financial Projections - Dazhong Public Utilities (01635.HK) projects net profit between 350 million to 500 million yuan in 2025, an increase of 50.12% to 114.46% [3] - Chunli Medical (01858.HK) expects net profit of 245 million to 288 million yuan in 2025, a rise of 96.01% to 130.41% [3] - Yujian Xiaomian (02408.HK) anticipates net profit between 100 million to 115 million yuan in 2025, an increase of approximately 64.7% to 89.5% [4] - China Railway (00390.HK) has recently won several major projects with a total bid amount of approximately 43.292 billion yuan [5] - Sunny Optical Technology (02382.HK) expects net profit between 4.5886 billion to 4.7235 billion yuan in 2025, a year-on-year increase of about 70.0% to 75.0% [6] - New天绿色能源 (00956.HK) expects to complete a cumulative power generation of 15.2104 million MWh in 2025, a year-on-year increase of 7.71% [7] Institutional Views - Guoyuan International suggests that Hong Kong stocks may continue to outperform U.S. stocks due to fiscal cliff and geopolitical factors, benefiting from a trend of diminishing dollar credit [8] - Huatai Securities believes that technology and cyclical "consumables" are likely to lead the rebound in Hong Kong stocks, supported by improved macro data and stable funding conditions [9] - CITIC Securities anticipates that the spring market for Hong Kong stocks will continue, with large-cap stocks showing relative gains and growth sectors supported by policy performing better [9]

Market Performance - The Hong Kong stock market opened lower on January 30, with the Hang Seng Index dropping by 496.82 points, a decline of 1.78%, closing at 27,471.27 points [1] - The Hang Seng Tech Index fell by 104.83 points, down 1.79%, to 5,736.27 points, while the National Enterprises Index decreased by 2.08% to 9,354.3 points [1] - Major tech stocks experienced declines, with Alibaba down 2.71%, Tencent down 1.53%, and JD Group down 1.4% [1] Company Earnings Forecasts - Guoquan (02517.HK) expects revenue for 2025 to be approximately 7.75 billion to 7.85 billion yuan, a year-on-year increase of about 19.8% to 21.3%, with net profit projected at 443 million to 463 million yuan, up 83.7% to 92.0% [2] - Sunny Optical Technology (02382.HK) anticipates a net profit of 4.5886 billion to 4.7235 billion yuan for 2025, representing a year-on-year increase of approximately 70.0% to 75.0% [3] - Baidu (02315.HK) forecasts revenue of 1.369 billion to 1.389 billion yuan for 2025, with a net profit of 162 million to 182 million yuan, reflecting a significant increase of 384.26% to 443.88% [3] - Spring Medical (01858.HK) expects a net profit of 245 million to 288 million yuan for 2025, an increase of 96.01% to 130.41% [4] - Encounter Small Noodles (02408.HK) projects a net profit between 100 million to 115 million yuan for 2025, an increase of approximately 64.7% to 89.5% [5] - Macro Credit Development (09930.HK) issued a profit warning, expecting a decline in shareholder profit by 70% to 90% for 2025 [6] - Financial Street Securities (01476.HK) issued a profit alert, expecting a shareholder profit increase to approximately 327 million yuan for 2025 [7] Industry Insights - China Railway (00390.HK) recently won several major engineering contracts with a total bid amount of approximately 43.292 billion yuan [8] - New天绿色能源 (00956.HK) reported a cumulative power generation of 15.2104 million MWh for 2025, a year-on-year increase of 7.71% [9] - Huayi Pharmaceutical (01276.HK) received acceptance for a new indication application for its innovative drug, which may become a new treatment option for patients with unresectable liver cancer [9] - Citic Securities suggests focusing on three main lines in the short term: biomanufacturing, embodied intelligence, and 6G technology [11] - Guoyuan International believes that the Hong Kong stock market may continue to outperform the US market due to factors such as fiscal cliffs and geopolitical issues, benefiting from the low long-term valuation levels [12]

Market Performance - The Shanghai Composite Index rose by 0.16% to 4157.98 points, while the Shenzhen Component fell by 0.3% and the ChiNext Index dropped by 0.57%[1] - The Hong Kong Hang Seng Index increased by 0.51% to 27968.09 points, with the Hang Seng Technology Index declining by 1% and the Hang Seng China Enterprises Index rising by 0.42%[1] - The total market turnover in Hong Kong was 3319.942 million HKD[1] Currency and Economic Relations - The U.S. Treasury Department labeled the Chinese yuan as "severely undervalued" and urged China to allow timely appreciation of its currency[12] - A survey by Goldman Sachs indicated that the majority of investors expect the yuan to appreciate against the U.S. dollar this year[8] Corporate Earnings - Apple reported a record quarterly revenue of 143.8 billion USD, exceeding Wall Street expectations, with a 38% increase in revenue from China[12] - The anticipated net profit for Sunny Optical Technology is expected to increase by 70% to 75%, reaching approximately 4.589 to 4.724 billion RMB[14] Bilateral Agreements - China and the UK reached 11 positive outcomes during Prime Minister Keir Starmer's visit, including the establishment of a yuan clearing bank in the UK and a reduction in whisky import tariffs from 10% to 5%[12]

Market Performance - The Shanghai Composite Index rose by 0.16% to 4157.98 points, while the Shenzhen Component fell by 0.3% and the ChiNext Index dropped by 0.57%[1] - The Hong Kong Hang Seng Index increased by 0.51% to 27968.09 points, with the Hang Seng Tech Index declining by 1% and the Hang Seng China Enterprises Index rising by 0.42%[1] - The total market turnover in Hong Kong was 3319.942 million HKD[1] Currency and Economic Relations - The U.S. Treasury Department labeled the Chinese yuan as "severely undervalued" and urged China to allow timely appreciation of its currency[12] - China and the UK reached several positive outcomes during Prime Minister Keir Starmer's visit, including the establishment of a yuan clearing bank in the UK[12] Corporate Earnings - Apple reported a record quarterly revenue of 143.8 billion USD, exceeding Wall Street expectations, with a 38% increase in revenue from China[12] - The anticipated net profit for Sunny Optical Technology is expected to increase by 70% to 75%, reaching approximately 4.589 to 4.724 billion RMB[14] - Baidu's expected net profit for the year is projected to increase by 384% to 443%[14] Commodity Market Trends - Gold prices fell from above 5500 USD per ounce, experiencing a significant drop of 5.7% in a single day due to profit-taking and a stronger dollar[12] - Copper prices surged by 10.1%, reaching a historic high of over 14,400 USD per ton, driven by speculative trading in China[12]